Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age =\> 18 years
Histologic diagnosis of adenocarcinoma of the prostate
Bulky intermediate risk, high risk or metastatic prostate cancer
Bulky intermediate risk: cT1-2 with \>50% of diagnostic biopsy cores containing cancer and Gleason 6 or 7 and prostate specific antigen (PSA) \>10 and ≤20 OR
High risk:
cT1-2 with Gleason score ≥8; or cT1-2 with PSA \>20; or cT3 OR N+ and/or M1 disease OR Newly diagnosed hormone-refractory prostate cancer - Intention to treat using radiotherapy +/- concurrent and adjuvant hormonal therapy
Intention to treat with radiotherapy, hormonal therapy, other systemic treatment for prostate cancer, or a combination of these according to the Princess Margaret Genitourinary Site policies.
Previous or concurrent anti-cancer therapy for the PET FAZA target lesion allowed
Ability to provide written informed consent to participate in the study
You may not be if
Inability to lie supine for more than 60 minutes
Patients taking the drug disulfiram (Antabuse)
Contraindications for MRI: only applicable in cases where the PET FAZA target lesion is identified as the prostate gland. Patients with target lesions at other anatomic sites will not undergo MR imaging.
